Annual Accounts Receivable
$600.00
-$400.00-40.00%
December 31, 2022
Summary
- As of February 20, 2025, NAVB annual accounts receivable is $600.00, with the most recent change of -$400.00 (-40.00%) on December 31, 2022.
- During the last 3 years, NAVB annual accounts receivable has risen by +$600.00 (+100.00%).
- NAVB annual accounts receivable is now -99.98% below its all-time high of $2.50 million, reached on December 31, 2015.
Performance
NAVB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$30.90 K
-$13.80 K-30.87%
September 30, 2023
Summary
- As of February 20, 2025, NAVB quarterly accounts receivable is $30.90 thousand, with the most recent change of -$13.80 thousand (-30.87%) on September 30, 2023.
- Over the past year, NAVB quarterly accounts receivable has dropped by -$13.80 thousand (-30.87%).
- NAVB quarterly accounts receivable is now -99.76% below its all-time high of $12.96 million, reached on March 31, 2018.
Performance
NAVB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
NAVB Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -40.0% | -30.9% |
| 3 y3 years | +100.0% | -30.9% |
| 5 y5 years | +100.0% | -30.9% |
NAVB Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -40.0% | at low | -80.1% | +5050.0% |
| 5 y | 5-year | -99.0% | -100.0% | -98.2% | -100.0% |
| alltime | all time | -100.0% | -100.0% | -99.8% | -100.0% |
Navidea Biopharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $30.90 K(-30.9%) |
| Jun 2023 | - | $44.70 K(+44.2%) |
| Mar 2023 | - | $31.00 K(+5066.7%) |
| Dec 2022 | $600.00(-40.0%) | $600.00(-99.6%) |
| Sep 2022 | - | $155.20 K(+415.6%) |
| Jun 2022 | - | $30.10 K(-74.0%) |
| Mar 2022 | - | $115.80 K(>+9900.0%) |
| Dec 2021 | $1000.00(-98.3%) | $1000.00(-98.3%) |
| Dec 2020 | $58.80 K(>+9900.0%) | $58.80 K(-96.5%) |
| Mar 2020 | - | $1.70 M(>+9900.0%) |
| Dec 2019 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2019 | - | $145.80 K(-29.5%) |
| Jun 2019 | - | $206.90 K(+1989.9%) |
| Mar 2019 | - | $9900.00(-20.2%) |
| Dec 2018 | $12.40 K(>+9900.0%) | $12.40 K(-85.7%) |
| Sep 2018 | - | $86.90 K(-76.8%) |
| Jun 2018 | - | $373.90 K(-97.1%) |
| Mar 2018 | - | $12.96 M(>+9900.0%) |
| Dec 2017 | $0.00(-100.0%) | $0.00(-100.0%) |
| Dec 2016 | $18.40 K(-99.3%) | $18.40 K(-99.3%) |
| Dec 2015 | $2.50 M(+206.0%) | $2.50 M(+30.8%) |
| Sep 2015 | - | $1.91 M(+4.4%) |
| Jun 2015 | - | $1.83 M(+51.1%) |
| Mar 2015 | - | $1.21 M(+48.3%) |
| Dec 2014 | $816.50 K(-29.0%) | $816.50 K(-44.3%) |
| Sep 2014 | - | $1.47 M(+200.8%) |
| Jun 2014 | - | $487.10 K(-17.0%) |
| Mar 2014 | - | $586.70 K(-49.0%) |
| Dec 2013 | $1.15 M(+6437.5%) | $1.15 M(+629.2%) |
| Sep 2013 | - | $157.80 K(+82.9%) |
| Jun 2013 | - | $86.30 K(+393.1%) |
| Mar 2013 | - | $17.50 K(-0.6%) |
| Dec 2012 | $17.60 K(+11.4%) | $17.60 K(-22.8%) |
| Sep 2012 | - | $22.80 K(+159.1%) |
| Jun 2012 | - | $8800.00(-65.9%) |
| Mar 2012 | - | $25.80 K(+63.3%) |
| Dec 2011 | $15.80 K(-99.2%) | $15.80 K(-91.2%) |
| Sep 2011 | - | $179.90 K(-91.2%) |
| Jun 2011 | - | $2.03 M(+11.4%) |
| Mar 2011 | - | $1.82 M(-10.9%) |
| Dec 2010 | $2.05 M | $2.05 M(+48.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2010 | - | $1.38 M(-27.1%) |
| Jun 2010 | - | $1.90 M(+67.0%) |
| Mar 2010 | - | $1.14 M(-14.7%) |
| Dec 2009 | $1.33 M(-18.1%) | $1.33 M(-4.4%) |
| Sep 2009 | - | $1.39 M(+21.5%) |
| Jun 2009 | - | $1.15 M(-32.0%) |
| Mar 2009 | - | $1.69 M(+3.6%) |
| Dec 2008 | $1.63 M(+0.3%) | $1.63 M(+23.6%) |
| Sep 2008 | - | $1.32 M(+16.4%) |
| Jun 2008 | - | $1.13 M(-6.8%) |
| Mar 2008 | - | $1.21 M(-25.2%) |
| Dec 2007 | $1.62 M(+30.2%) | $1.62 M(+16.9%) |
| Sep 2007 | - | $1.39 M(+21.4%) |
| Jun 2007 | - | $1.14 M(+16.9%) |
| Mar 2007 | - | $977.90 K(-21.5%) |
| Dec 2006 | $1.25 M(+85.2%) | $1.25 M(+88.0%) |
| Sep 2006 | - | $662.80 K(-27.3%) |
| Jun 2006 | - | $911.20 K(+28.2%) |
| Mar 2006 | - | $710.80 K(+5.6%) |
| Dec 2005 | $673.00 K(+63.4%) | $673.00 K(-23.1%) |
| Sep 2005 | - | $874.60 K(+135.7%) |
| Jun 2005 | - | $371.00 K(-59.3%) |
| Mar 2005 | - | $912.10 K(+121.4%) |
| Dec 2004 | $411.90 K(-62.8%) | $411.90 K(-44.8%) |
| Sep 2004 | - | $746.40 K(+30.6%) |
| Jun 2004 | - | $571.30 K(-30.5%) |
| Mar 2004 | - | $821.70 K(-25.8%) |
| Dec 2003 | $1.11 M(+48.5%) | $1.11 M(-2.3%) |
| Sep 2003 | - | $1.13 M(-24.7%) |
| Jun 2003 | - | $1.51 M(+64.3%) |
| Mar 2003 | - | $916.50 K(+22.8%) |
| Dec 2002 | $746.10 K(+33.0%) | $746.10 K(+77.5%) |
| Sep 2002 | - | $420.40 K(-10.2%) |
| Jun 2002 | - | $468.10 K(+151.7%) |
| Mar 2002 | - | $186.00 K(-66.9%) |
| Dec 2001 | $561.10 K(+53.7%) | $561.10 K(+1088.8%) |
| Sep 2001 | - | $47.20 K(-65.4%) |
| Jun 2001 | - | $136.30 K(-72.1%) |
| Mar 2001 | - | $488.60 K(+33.8%) |
| Dec 2000 | $365.10 K(-82.4%) | $365.10 K(-82.4%) |
| Dec 1998 | $2.07 M(+160.9%) | $2.07 M(+160.9%) |
| Dec 1997 | $793.40 K | $793.40 K |
FAQ
- What is Navidea Biopharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual accounts receivable year-on-year change?
- What is Navidea Biopharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly accounts receivable year-on-year change?
What is Navidea Biopharmaceuticals annual accounts receivable?
The current annual accounts receivable of NAVB is $600.00
What is the all time high annual accounts receivable for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual accounts receivable is $2.50 M
What is Navidea Biopharmaceuticals annual accounts receivable year-on-year change?
Over the past year, NAVB annual accounts receivable has changed by -$400.00 (-40.00%)
What is Navidea Biopharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of NAVB is $30.90 K
What is the all time high quarterly accounts receivable for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly accounts receivable is $12.96 M
What is Navidea Biopharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, NAVB quarterly accounts receivable has changed by -$13.80 K (-30.87%)